by Deborah Erickson
The 1980s were a good time to be in the Italian pharmaceutical business. Drug prices were high, and multinational firms,...
Recordati Refocuses
Diversification didn't pay off very well for Italy's Recordati Industria Chimica & Farmaceutica SPA. The company's revised growth strategy depends mostly on developing assets it already has, principally its fine chemicals business, and an already-approved calcium antagonist called lercanidipine.